Acknowledgements Natalie Weir, for help with the charts. Conclusion Toxicities were broadly as expected and interestingly, most care issues were associated with erlotinib; skin and gastrointestinal toxicity and patient education. When considering care across boundaries, the electronic pharmacy cancer care plan will provide adequate information on regimen, dose, care issues, toxicity and dates of treatment. Care providers in primary care will need to have access to abbreviated treatment protocols to assist with early detection of toxicity and management. The IT infrastructure is in place – it rests with the clinicians now to drive redesign to meet the 2020 vision. Aim To describe a lung cancer population in terms of age, gender, diagnosis, co-morbidities, performance status and smoking status To quantify SACT used 1 st & 2 nd line To identify patient reported toxicities attributed to SACT To identify pharmaceutical care issues resulting from SACT To quantify episodes of unscheduled care, reasons and length of stay To establish if SACT could be delivered out with specialist units Fiona MacLean, Lead Clinical Pharmacist New Victoria Hospital, NHS Greater Glasgow & Clyde Introduction NHS Greater Glasgow & Clyde’s (GGC) cancer services are to meet the strategic aims of NHS Scotland’s 2020 Vision. Integrating health and social care requires new models of care which cross traditional boundaries. Shared pharmacy records with primary care, utilising e-health strategies, is a primary aim of GGC pharmacy. How do we identify populations suitable for shared care? What are the pharmaceutical care needs of cancer patients and how will pharmacists regardless of care setting, contribute to their care? What is the key information to be communicated? Lung cancer patients are perceived as being an at risk population due to multiple co-morbidities and frequent admissions to hospital. Care switches between oncology, respiratory, primary care and palliative care with multiple hand offs. Implementing e-health solutions to facilitate care for patients with lung cancer will be transferable to other patient groups. Get it right here, and we have a model of care for the future. Results Ten regimens were prescribed as 1 st or 2 nd line therapy. Twelve toxicities were identified across all SACT given and recorded as one instance per cycle irrespective of duration (graphs 1 & 2). Thirteen pharmaceutical care issues were associated with lung cancer SACT and recorded once per cycle (graph 3). There were 18 episodes of unscheduled care in total; mean length of stay was 5.2 days. The principal reason for admission was haematological toxicity +/- infection. A retrospective analysis of a cohort of lung cancer patients: co-morbidities, toxicities, pharmaceutical care issues and unscheduled care. Do we really know our patient population? Method A retrospective analysis of 50 patients receiving lung cancer SACT between in New Victoria Hospital, Glasgow was undertaken. Data was collected using the electronic patient record and Chemocare® as the source and recorded on an Excel spreadsheet. Every third patient was included. Results 50 patients were included in the analysis. Baseline characteristics at cycle 1 as shown in table 1. Table 1: Patient characteristics Age range (yrs)38-82yrs; mean age 64.56yrs Baseline weight (kg)39-97kg; mean weight 66.89kg DiagnosisNSCLC N=29 SCLC N=20 Large cell N=1 GenderM=14 F=15 M=9 F=11 F=1 Smoking status NS -non-smoker NR - not recorded Smoker=16 NS= 10 NR=3 Smoker=12 NS= 4 NR=4 NS =1 Performance status Not recorded500 Baseline eGFR > <39000 Co-morbidities Cardiovascular10110 Cerebrovascular210 CNS510 Endocrine641 GI410 Musculoskeletal430 Renal110 Respiratory831 Skin200 Other520 Graph 2: Toxicity reported with SACT Graph 1: Summary data Graph 3: Pharmaceutical care issues associated with SACT